Bristol Myers Squibb (BMY) Has a Growth-Portfolio Bridge the Patent-Cliff Label Misses

[ad_1] Why Bristol Myers is more than a patent-cliff story Bristol Myers Squibb is often reduced to a familiar big-pharma problem: legacy blockbusters lose exclusivity, revenue steps down, and the market waits to see whether the pipeline can plug the…






